Drug Profile
Research programme: neuroprotection/stroke therapies - Ambit Biosciences
Alternative Names: AB 087; AB30000; AB30087Latest Information Update: 01 Feb 2011
Price :
$50
*
At a glance
- Originator Ambit Biosciences Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders; Stroke
Most Recent Events
- 01 Feb 2011 Discontinued - Preclinical for Neurological disorders (Prevention) in USA (unspecified route)
- 01 Feb 2011 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 20 Apr 2006 This programme is still in active development